Efficacy Of Macular Photocoagulation When Given In The Early Or Late Period After Single Intravitreal Bevacizumab Injection In Terms Of Central Foveal Thickness Change And Visual Acuity Gain

2021 ◽  
Vol 23 (01) ◽  
pp. 267-279
Author(s):  
Aaska Sapan Shah ◽  
Naimish Haribhai Mahaliya ◽  
Sapan Snehalbhai Shah ◽  
Jigar Jitendrabhai Joshi
Keyword(s):  
Visual Acuity ◽  
Intravitreal Bevacizumab ◽  
Late Period ◽  
Foveal Thickness ◽  
Thickness Change ◽  
Central Foveal Thickness ◽  
Intravitreal Bevacizumab Injection ◽  
Bevacizumab Injection

scholarly journals Combined Intravitreal Bevacizumab and Laser Photocoagulation to Treat Retinal Arterial Macroaneurysms

2021 ◽  
Vol 62 (8) ◽  
pp. 1053-1060
Author(s):  
Tae Hoon Kim ◽  
Chang Zoo Kim ◽  
Seung Uk Lee ◽  
Sang Joon Lee
Keyword(s):  
Visual Acuity ◽  
Laser Photocoagulation ◽  
Lipid Level ◽  
Intravitreal Bevacizumab ◽  
Macular Thickness ◽  
Intravitreal Bevacizumab Injection ◽  
Photocoagulation Treatment ◽  
The Mean ◽  
Bevacizumab Injection

Purpose: To investigate the effects of intravitreal bevacizumab injection combined with laser photocoagulation in patients with retinal microaneurysms.Methods: We retrospectively reviewed the medical records of 21 eyes of 21 patients who underwent intravitreal bevacizumab injection and/or laser photocoagulation to treat retinal macroaneurysms. Eleven eyes received the combination therapy (CT) and 10 eyes monotherapy (MT) (either bevacizumab injection or laser photocoagulation). Changes in visual acuity, central macular thickness, macroaneurysm size and location, blood pressure, and the lipid level were compared between the two groups.Results: The mean patient age was 74.0 ± 10.5 years and the mean study period 7.0 ± 5.3 months. The mean macroaneurysm diameter of the CT group was 480.00 ± 292.30 μm and that of the MT group 328.75 ± 87.09 μm. The diameter was significantly larger in the CT group (p = 0.002). The initial visual acuities were 0.91 ± 0.66 and 0.88 ± 0.83 in the CT and MT groups, respectively. At the 4-month follow-up, the visual acuities were 0.33 ± 0.26 and 0.17 ± 0.29 in the CT and MT groups, respectively, and had significantly improved only in the CT group (p = 0.042). The initial central macular thicknesses were 441.82 ± 226.81 and 541.63 ± 401.97 μm in the CT and MT groups, respectively. At the 4-month follow-up, the figures were 293.60 ± 46.10 and 269.00 ± 48.34 μm in the CT and MT groups, respectively, and had significantly decreased only in the CT group (p = 0.043). Compared to the initial findings, the proportion of patients whose final visual acuities improved by more than two lines were 73% and 40%, respectively, thus significantly higher in the CT group (p < 0.001).Conclusions: Combined intravitreal bevacizumab injection and laser photocoagulation treatment of retinal macroaneurysms improve visual acuity and decrease macular thickness.

Can an Intraoperative Bevacizumab Injection Prevent Recurrent Postvitrectomy Diabetic Vitreous Hemorrhage?

2009 ◽  
Vol 19 (4) ◽  
pp. 618-621 ◽  
Author(s):  
Mario R. Romano ◽  
Syed Khurshid Gibran ◽  
Joaquin Marticorena ◽  
David Wong ◽  
Henrich Heimann
Keyword(s):  
Visual Acuity ◽  
Pars Plana Vitrectomy ◽  
Intravitreal Bevacizumab ◽  
Vitreous Hemorrhage ◽  
Diabetic Patients ◽  
Intravitreal Bevacizumab Injection ◽  
Pars Plana ◽  
Grade 3 ◽  
Bevacizumab Injection

Purpose To evaluate the recurrence of vitreous hemorrhage (VH) in patients treated with intravitreal bevacizumab (IVB) injection (2.5 mg/0.1 mL) intraoperatively at the end of vitrectomy for treatment of diabetic nonclearing VH. Methods A prospective pilot study of 30 eyes of 28 consecutive diabetic patients who underwent pars plana vitrectomy and IVB injection intraoperatively at the end of vitrectomy was performed. The amount of VH was graded with slit lamp biomicroscopy by three masked retinal specialists from grade 0 to grade 3. Main outcome measures were rate of recurrence of the VH, improvement in visual acuity, incidence of cataract formation, and postoperative complications through a follow-up of 6 months. Results The percentage of severe recurrent VH with no fundus details (grade 3) was 7%, 13%, 27%, and 30%, respectively, at 7 days and 1-, 3-, and 6-month follow-up. At 6-month follow-up, the best-corrected visual acuity improved from 1.00 to 0.4 logMAR (p=0.01) in 21 out of 30 eyes (70%). Nine out 20 (40%) phakic patients developed cataract during the follow-up period, and 7 (31%) of them underwent cataract surgery. Conclusions The study suggests that intravitreal bevacizumab injection cannot prevent rebleeding in eyes undergoing pars plana vitrectomy for treatment of diabetic vitreous hemorrhage.

scholarly journals Functional and structural outcome after vitrectomy combined with subretinal rtPA Injection with or without additional intravitreal Bevacizumab injection for submacular hemorrhages

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0250587
Author(s):  
Annekatrin Rickmann ◽  
Lina R. Paez ◽  
Maria della Volpe Waizel ◽  
Lukas Bisorca-Gassendorf ◽  
André Schulz ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Case Series ◽  
Intravitreal Bevacizumab ◽  
Age Related Macular Degeneration ◽  
Subretinal Space ◽  
Intravitreal Bevacizumab Injection ◽  
Age Related ◽  
The Mean ◽  
Group B ◽  
Bevacizumab Injection

Background To analyze the functional and anatomical outcome after vitrectomy with subretinal rtPA (recombinant tissue plasminogen activator) combined with or without an intravitreal Bevacizumab injection. Patients and methods Retrospective, consecutive case series of 31 pseudophakic patients with submacular hemorrhage (SMH) due to neovascular age-related macular degeneration (AMD) treated with vitrectomy, subretinal rtPA and pneumatic air displacement with or without an additional intravitreal Bevacizumab injection. The primary endpoints were best-corrected visual acuity (BCVA), and central macular thickness (CMT) measured by SD‑OCT. The secondary endpoint was a displacement of hemorrhage from the subretinal space three months after surgery. Results 31 eyes of 31 patients were treated with vitrectomy and subretinal rtPA. 17/31 were treated simultaneously with an intravitreal Bevacizumab injection (group +B) and 14/31 without (group -B). The mean visual acuity improved significantly in both groups (from 1.37±0.39 to 1.03±0.57 logMAR in +B and from 1.48±0.48 to 1.01±0.38 logMAR in group –B, p<0.05). The mean CMT decreased in group +B from 607±179 μm to 424±205 μm (p = 0.2) and in group –B from 722±216 μm to 460±202 μm (p<0.05). A central displacement of the hemorrhage could be achieved in 47% in group +B, whereas in group -B displacement could be achieved in 50% (p = 0.44). Conclusions Vitrectomy with subretinal rtPA injection and air tamponade with or without simultaneous intravitreal Bevacizumab injection displaces SMH and improves BCVA effectively. In comparison, the postoperative outcome is comparable regardless of whether or not intravitreal bevacizumab is applied simultaneously.

scholarly journals Serial Intravitreal Bevacizumab Injections Slow the Progression of Radiation Maculopathy Following Iodine-125 Plaque Radiotherapy

2016 ◽  
Vol 10 (1) ◽  
pp. 103-110 ◽  
Author(s):  
Andrew W. Stacey ◽  
Hakan Demirci
Keyword(s):  
Visual Acuity ◽  
Fluorescein Angiography ◽  
Late Phase ◽  
Treatment Strategies ◽  
Choroidal Melanoma ◽  
Intravitreal Bevacizumab ◽  
Intravitreal Bevacizumab Injection ◽  
Plaque Radiotherapy ◽  
The Mean ◽  
Bevacizumab Injection

Background and Objective: To assess the outcomes of intravitreal bevacizumab injection in the management of radiation maculopathy secondary to plaque radiotherapy, and to identify optimal treatment strategies. Study Design: A retrospective review of all choroidal melanoma patients at one referral center who were treated with plaque radiotherapy, subsequently developed radiation maculopathy, and received intravitreal bevacizumab. Results: A total of 31 patients were identified. The mean visual acuity decreased three Snellen lines in the year leading up to the first bevacizumab injection. After initiating injection therapy, the mean visual acuity remained stable for 9 months. The change in visual acuity of patients who received injections within 90 days of previous injections was significantly better than the visual acuity of those who received injections more than 90 days apart (p=0.0003). Patients who demonstrated late-phase macular leakage on fluorescein angiography at the time of the first bevacizumab injection had better long-term visual acuity outcomes than patients who had no evidence of macular leakage (average of one line improvement of vision vs. ten line loss of vision, p=0.03). Conclusions: Intravitreal bevacizumab injection was effective in stabilizing visual acuity in patients with radiation maculopathy. Patients benefited most from injections administered every 90 days or sooner. Fluorescein angiography can help identify patients who will respond favorably to treatment.

Meta-herpetic ulcer following intravitreal bevacizumab

2020 ◽  
pp. 112067212095203
Author(s):  
Geeta Behera ◽  
Tanmay Gokhale ◽  
Amit Kumar Deb ◽  
Krishna Ramesh Babu
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Visual Acuity ◽  
Type 2 Diabetes Mellitus ◽  
Severe Pain ◽  
Intravitreal Bevacizumab ◽  
Intravitreal Bevacizumab Injection ◽  
The Right ◽  
Bevacizumab Injection

Purpose: To report a case of meta-herpetic ulcer that developed after intravitreal bevacizumab injection. Methods: A 55-year-old man with type 2 diabetes mellitus and nephropathy received intravitreal injection of bevacizumab in his right eye for proliferative diabetic retinopathy with macular edema. Results: Two days after the injection, the patient presented with severe pain, redness, and photophobia, and decreased visual acuity in the right eye. The cornea showed a paracentral epithelial erosion with heaped margins with subepithelial haze and punctate keratopathy, and high intraocular pressure. He initially responded to topical antiviral and antiglaucoma medications. However, it rapidly progressed to a geographic ulcer on initiation of mild steroid and became resistant to conventional medical management. His nephropathy precluded treatment with full dose of systemic antivirals and antiglaucoma drugs. Subsequently, it healed after a paramedian tarsorrhaphy was performed. Conclusion: Herpetic epithelial keratitis following intravitreal bevacizumab is a rare occurence. However, this case is the first report of progression to a meta-herpetic ulcer.

Intravitreal Bevacizumab in Refractory Uveitic Macular Edema: One-year Follow-up

2009 ◽  
Vol 19 (4) ◽  
pp. 622-629 ◽  
Author(s):  
Rene A. Cervantes-Castañeda ◽  
Gian Paolo Giuliari ◽  
Michael J. Gallagher ◽  
Taygan Yilmaz ◽  
Rebecca E. Macdonell ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Combination Therapy ◽  
Macular Edema ◽  
Triamcinolone Acetonide ◽  
Intravitreal Bevacizumab ◽  
Central Macular Thickness ◽  
Intravitreal Bevacizumab Injection ◽  
Uveitic Macular Edema ◽  
The Mean ◽  
Bevacizumab Injection

Purpose Uveitis is a major cause of ocular morbidity in developed countries. It has been demonstrated that macular edema is a significant cause of decreased visual acuity and macular edema in these patients. In this article, we evaluate the long-term outcome of intravitreal bevacizumab in the treatment of refractory uveitic macular edema. Methods In this retrospective, noncomparative, interventional case series, uveitic patients with macular edema who were refractory to conventional therapy and who were treated with intravitreal bevacizumab were identified and assessed. Best-corrected visual acuity and optical coherence tomography central macular thickness measurements were collected and analyzed with correlative statistical analysis, including the use of Student paired t-test, Kaplan-Meier, and linear regression analysis. Results Twenty-nine eyes of 27 patients with diverse uveitic etiologies were analyzed and followed up at 1 year. Thirteen patients received a single intravitreal bevacizumab injection. Six patients required a second intravitreal bevacizumab injection, while 10 patients received combination therapy of intravitreal bevacizumab and triamcinolone acetonide. Baseline mean logMAR visual acuity was −0.59. At 1 year, the mean logMAR visual acuity was −0.42± 0.36 (p=0.0045). Baseline mean central macular thickness was 383.66 μm. At 1 year, the mean thickness was 294.32±110.87 (p=0.0007). Conclusions Intravitreal bevacizumab is a useful and therapeutically beneficial agent in the treatment of refractory uveitic macular edema. Some patients will require adjunctive intravitreal bevacizumab injections or the use of combination therapy with intravitreal triamcinolone acetonide.

scholarly journals Visual outcomes in Patients with Diabetic Macular Oedema undergoing Cataract Surgery with or without Intravitreal Bevacizumab

1970 ◽  
Vol 12 (3) ◽  
pp. 135-139
Author(s):  
Mazhar Hassan Hassan ◽  
Aziz Ur Rehman ◽  
Umair Qidwai ◽  
Rashid Alvi ◽  
Nasir Bhatti ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Cataract Surgery ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Intravitreal Bevacizumab ◽  
Control Group ◽  
Open Label ◽  
Intravitreal Bevacizumab Injection ◽  
Randomised Controlled ◽  
Bevacizumab Injection

Aims: To evaluate the efficacy of a single intravitreal bevacizumab injection after cataract surgery for the management of postoperative decrease in vision in patients with diabetic macular oedema.Methods: In this randomised controlled open-label parallel group study of 60 patients with diabetic macular oedema and lens opacity (grade ≥3), 30 eyes received a single intravitreal bevacizumab injection after cataract surgery, and 30 control eyes did not receive bevacizumab. The primary endpoint was change in best-corrected visual acuity 6 weeks after operation compared with that at baseline using the Snellen visual acuity chart.Results: Postoperative visual acuity was significantly different between the group receiving bevacizumab and the control group (p<0.005). All patients in the bevacizumab group had postoperative visual acuities above 6/18 with 27 patients having visual acuities of 6/12 or better compared with 6 patients in the control group. None of the patients in the bevacizumab group had visual acuities less than 6/18 compared with 11 patients in the control group.Conclusion: Intravitreal bevacizumab after cataract surgery appears to be beneficial for preventing postoperative visual loss in eyes with diabetic retinopathy by reducing the risk of macular thickening.

Sign in / Sign up

Export Citation Format

Share Document